about the author

ENDPOINTS

editor@endpointsnews.com

author articles

Lex­eo brings in $95M; FDA lifts hold on Nurix can­cer tri­al

Last year
News Briefing

Ul­ti­movac­s' melanoma vac­cine fails in PhII; Re­genxbio’s $140M of­fer­ing

Last year
News Briefing

Bridge­Bio's $250M of­fer­ing; Vi­iV's PhI da­ta for ul­tra-long-act­ing HIV treat­ment

Last year
News Briefing

Viking's $350M of­fer­ing; Bak­er Broth­ers leads an­oth­er PIPE

Last year
News Briefing

De­nali’s $500M place­ment; Brain health start­up rais­es $26M

Last year
News Briefing

Mer­ri­mack to dis­solve af­ter record­ing $225M mile­stone; Co­gen­t's $225M place­ment

Last year
News Briefing

Ku­ra’s stock jumps on PhIb read­out; FDA lifts hold on IN­mune Bio pro­gram; Nanobi­otix’s $20M mile­stone

Last year
News Briefing

Mer­ck inks deal with Un­nat­ur­al Prod­ucts; CG On­col­o­gy’s up­sized IPO; Lo­cus gets $24M from BAR­DA

Last year
News Briefing

Doud­na’s new ven­ture; Aclaris CEO to step down; Tome’s $114M liv­er dis­or­der deal with Genevant

Last year
News Briefing

#JPM24 quick hits: Io­n­is on part­ner­ship’s pros and cons; No­vo Ven­tures has $600M to spend; Are small mol­e­cules ...

Last year
R&D

#JPM24 quick hits: Vibe check; Maze’s next turn; AI at phar­ma com­pa­nies + more

Last year
Deals
AI

#JPM24 quick hits: A 'great year for M&A'; an op­ti­mistic Sarep­ta; Pfiz­er's CEO + more

Last year
Deals
R&D

Rhythm li­cens­es obe­si­ty drug for $100M; Gala­pa­gos teams up with Brid­Gene; In­sil­i­co’s new deal

Last year
News Briefing

All the new drugs ap­proved in 2023: Alzheimer's and gene ther­a­py cap a five-year high

Last year
FDA+

J&J’s new part­ner­ship with Elek­trofi; Enyo rais­es €39M; Ar­row­head­'s $450M of­fer­ing

Last year
News Briefing

The­seus goes with Tang; Onc­ter­nal tri­al pa­tient dies; Lian­Bio sells drug rights to J&J

Last year
News Briefing

The 2023 win­ners and losers list: Who was up and who was down in bio­phar­ma

Last year
Pharma

Rock­et’s gene ther­a­py gets a PDU­FA date; SAB Bio­ther­a­peu­tics’ $130M; Acurx to move to PhI­II

Last year
News Briefing

An­tios re­port­ed­ly shut down; Clene's long-term ALS da­ta; Keytru­da, Lenvi­ma's lung can­cer fail­ures

Last year
News Briefing

The End­points 11: The biotech star­tups mak­ing the biggest bets with the most ex­cit­ing sci­ence in 2023

Last year
Startups
Special

Ex­clu­sive: Af­ter Cure­Vac, Ig­or Splaws­ki moves to RTW stealth start­up; Lyn­dra's Jes­si­ca Ballinger adds CEO ti­tle amid ...

Last year
Peer Review

Spe­cial re­port 2023: Meet 20 women re­shap­ing bio­phar­ma

Last year
Special

The 20(+2) un­der 40: Your guide to the next gen­er­a­tion of biotech lead­ers

3 years ago
Special

Every drug ap­proved in 2022: A year of few­er new prod­ucts, but gene ther­a­py firsts and new block­busters

3 years ago
R&D
Special
First page Previous page 9101112131415 Next page Last page
A service from the Financial Times